Stock Scorecard
Stock Summary for Xeris Biopharma Holdings Inc (XERS) - $1.85 as of 4/15/2024 10:44:19 PM EST
Total Score
7 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for XERS
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for XERS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for XERS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for XERS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for XERS
Financial Details for XERS
Company Overview |
|
|---|---|
| Ticker | XERS |
| Company Name | Xeris Biopharma Holdings Inc |
| Country | USA |
| Description | Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/8/2024 |
Stock Price History |
|
| Last Day Price | 1.85 |
| Last Day Price Updated | 4/15/2024 10:44:19 PM EST |
| Last Day Volume | 1,773,740 |
| Average Daily Volume | 2,018,481 |
| 52-Week High | 3.26 |
| 52-Week Low | 1.46 |
| Last Price to 52 Week Low | 26.71% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 99.80 |
| Sector PE | 62.54 |
| 5-Year Average PE | -2.24 |
| Free Cash Flow Ratio | 3.56 |
| Industry Free Cash Flow Ratio | 12.80 |
| Sector Free Cash Flow Ratio | 32.12 |
| Current Ratio Most Recent Quarter | 1.64 |
| Total Cash Per Share | 0.52 |
| Book Value Per Share Most Recent Quarter | -0.05 |
| Price to Book Ratio | 3.86 |
| Industry Price to Book Ratio | 5.60 |
| Sector Price to Book Ratio | 22.02 |
| Price to Sales Ratio Twelve Trailing Months | 1.64 |
| Industry Price to Sales Ratio Twelve Trailing Months | 14.20 |
| Sector Price to Sales Ratio Twelve Trailing Months | 7.31 |
Share Statistics |
|
| Total Shares Outstanding | 140,453,000 |
| Market Capitalization | 259,838,050 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 34.23% |
| Reported EPS 12 Trailing Months | -0.45 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -0.45 |
| Net Income Twelve Trailing Months | -62,255,000 |
| Net Income Past Year | -62,255,000 |
| Net Income Prior Year | -94,660,000 |
| Quarterly Revenue Growth YOY | 33.90% |
| 5-Year Revenue Growth | 64.60% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 72,451,000 |
| Total Cash Past Year | 72,451,000 |
| Total Cash Prior Year | 121,966,000 |
| Net Cash Position Most Recent Quarter | -118,481,000 |
| Net Cash Position Past Year | -118,481,000 |
| Long Term Debt Past Year | 190,932,000 |
| Long Term Debt Prior Year | 187,075,000 |
| Total Debt Most Recent Quarter | 190,932,000 |
| Equity to Debt Ratio Past Year | -0.04 |
| Equity to Debt Ratio Most Recent Quarter | -0.04 |
| Total Stockholder Equity Past Year | -6,782,000 |
| Total Stockholder Equity Prior Year | 45,187,000 |
| Total Stockholder Equity Most Recent Quarter | -6,782,000 |
Options |
|
| Put/Call Ratio | 0.09 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.15 |
| MACD Signal | -0.15 |
| 20-Day Bollinger Lower Band | 1.62 |
| 20-Day Bollinger Middle Band | 2.41 |
| 20-Day Bollinger Upper Band | 3.20 |
| Beta | 1.10 |
| RSI | 34.55 |
| 50-Day SMA | 2.34 |
| 200-Day SMA | 2.80 |
System |
|
| Modified | 4/13/2024 1:50:36 PM EST |